Research
Hormonal
Tirzepatide use is associated with a potential risk of acute deep vein thrombosis (DVT), particularly in patients with predisposing risk factors such as obesity, rapid weight loss, or dehydration.
If you are taking tirzepatide, be aware of signs of blood clots like swelling, pain, or redness in your arms or legs. While rare, this risk exists, especially if you are losing weight rapidly or are obese. Report these symptoms to your doctor immediately.
LimitedQualifiesLOW confidence
This case highlights a potential risk of thromboembolic events associated with tirzepatide. Clinicians need to be vigilant and exercise extreme caution as the emerging adverse event profile of this novel medication unfolds.
Why this rating
Based on a single case report and pharmacovigilance data, not randomized controlled trials.
Source
Acute Deep Vein Thrombosis in the Setting of Tirzepatide Use: A Case Highlighting Emerging Concerns
Kunal Sonavane et al. · JCEM Case Reports · 2025
DOI 10.1210/jcemcr/luaf248
case_report · n=1Cited 2×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →